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There is increasing scrutiny regarding overutilization of
diagnostic medical imaging tests due to both costs and
potential morbidity (1). Noninvasive cardiovascular imaging
has received considerable attention because its growth rate
exceeds other physician services without a similar increase in
disease prevalence (2). Thus, there is a need to thoroughly
evaluate new imaging techniques before implementation of
widespread clinical use and, perhaps from a more pragmatic
perspective, before payers will provide reimbursement. With
the development of each new imaging technique, the
threshold of evidence required to demonstrate clinical
utility above existing technology becomes higher, particu-
larly if other modalities are more widely available and
established.See page 826Numerous diagnostic tests are available for evaluating
patients with suspected coronary artery disease (CAD). The
natural evolution of this diagnostic developmental process
follows a common pathway: 1) proof of concept in phantom
and animal models; 2) small correlation studies in humans to
verify accuracy; and 3) single and multicenter human studies
to validate the results of the smaller studies. The ability of
a test to provide prognostic data and to risk-stratify patients
must then be assessed by examining patient outcomes in
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analysis of such prognostic studies. The next step would be
to examine whether this new diagnostic test in fact alters
physician decision-making processes. Finally, to justify its
role, cost-effectiveness of the new test would have to be
demonstrated.
Why do clinicians order diagnostic tests during the
evaluation process of patients with suspected or established
CAD? In many instances, the purpose is to risk-stratify
patients, such as before surgical procedures or after coro-
nary events, and for management of symptomatic patients.
Although radiographic coronary angiography can undoubt-
edly identify patients with high-risk anatomy (e.g., signiﬁ-
cant left main stenosis, triple vessel disease) or patients with
normal coronary anatomy, its invasive nature makes it less
than an ideal initial test. Furthermore, the atherosclerotic
process begins in the vessel wall and cannot be fully char-
acterized by invasive or noninvasive luminography. There-
fore, luminal diameter may have little prognostic relevance
unless we understand its physiological signiﬁcance (3).
Therefore, despite its clinical status as the gold standard for
diagnosing CAD, invasive radiograph angiography is not
likely to be the test of choice for most patients.
Therefore, in addition to making a correct diagnosis,
a preferred test needs to accurately identify low-risk patients
who will not beneﬁt from downstream testing, in effect
acting as a “gatekeeper” for other invasive and noninvasive
tests and procedures. Furthermore, once results of the tests
are negative, repeat testing in the near term should not be
required. The test must also identify high-risk patients who
would beneﬁt from downstream invasive angiography and/or
revascularization. To that end, although performance char-
acteristics such as sensitivity and speciﬁcity against a gold
standard (e.g., invasive angiography) are certainly relevant, it
can be argued that the prognostic performance of a test is an
even more important metric.
Over the past 2 decades, cardiac magnetic resonance
imaging (CMR) has grown from a research curiosity to
mainstream use at most medical centers. Previous meta-
analyses of stress CMR have focused on its diagnostic
performance in detecting CAD (4–7), while a recent trial
showed multiparametric CMR to have superior diagnostic
accuracy compared with myocardial perfusion imaging
(MPI) (8). In this issue of the Journal, Lipinski et al. (9)
elegantly summarize the evidence surrounding the prog-
nostic value of pharmacological stress CMR (including
dobutamine stress and vasodilator stress). Among 19 studies
involving nearly 12,000 patients with suspected or estab-
lished CAD followed up for a median of 25 months,
a positive stress CMR had a much higher risk of the
combined hard outcomes of cardiovascular death and
myocardial infarction (MI), with a pooled odds ratio (OR)
of 6.5; and higher annual rates of cardiovascular death (2.8%
vs. 0.3%) and nonfatal MI (2.6% vs. 0.4%). When expressed
in clinical terms, annualized event rates (AERs) were 4.9%
versus 0.8% for patients with positive and negative stress
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840CMR, respectively. Event rates were similar between those
undergoing vasodilator stress and dobutamine stress.
Furthermore, a subset of studies that reported results with
late gadolinium enhancement (LGE) demonstrated a higher
risk of adverse events when there was LGE present (OR:
3.82; AER of the combined outcome of cardiovascular death
and MI: 4.6% vs. 1.4%). This body of evidence supports the
excellent discriminatory ability of stress CMR with or
without LGE to risk-stratify patients with known or sus-
pected CAD.
The OR provides a convenient summary measure that
quantiﬁes the relative risks of the cumulative events at the
end of follow-up, but this summary statistic does not give an
indication of how risks may vary during the follow-up
period. Despite these limitations, the estimated short-
term AER for patients with a negative stress CMR seems
consistent with the low event rates observed after a negative
stress echocardiogram and stress radionuclide MPI (10). All
have the ability to identify patients with sufﬁciently low risk
for future events who can be managed medically, supporting
a similar “watch and wait” strategy for patients with negative
stress echocardiogram or MPI. These patients can safely
avoid further downstream testing and interventions.
What is a clinician to do, therefore, with the results of
a positive stress CMR? It remains to be resolved how the
prognostic information from stress CMR should be applied
to optimally guide patient management, particularly in an
era in which novel strategies such as fractional ﬂow reserve–
guided revascularization show promise (3).
There are several limitations to this meta-analysis (9).
There is heterogeneity between the study populations, with
likely different pretest probabilities of CAD, baseline risk
factors, and known CAD. These would inﬂuence event rates
regardless of test results, in addition to their effects on the
operating characteristics of the test itself. As recognized
by the authors, there is a mixture of prospective and retro-
spective studies. The deﬁnition of a positive CMR was
variable, and not all studies compared stress with rest
images. Ischemia was also quantiﬁed as a dichotomous
variable, rather than as a continuous variable (e.g., by extent
of ischemia). Most studies focused on the prognostic value
of the stress CMR or LGE portion of the examination, and
few examined the relative incremental predictive value of
combinations of various parameters obtained in a compre-
hensive stress CMR study.
Second, there are limitations to the generalizability of
their data (9). All but 1 study involved single-center reports
in which expert CMR readers interpreted the scans.
Interpretation of stress CMR remains highly dependent on
the skill and experience of the reader compared with more
established and accepted imaging modalities (11,12). Mis-
interpretation by nonexpert readers in a real-world setting
would likely cause the observed risk rates to regress toward
the mean, thereby decreasing the prognostic discriminating
ability of the test. About 30% of patients had known CAD,
and the data need to be taken in this context. Previousstudies using stress echocardiography or radionuclide MPI
used slightly lower risk populations; however, the AER of
patients with a negative CMR at 0.8% is comparably low.
In a real-world setting, this may underestimate the true risk
because many patients referred to a stress CMR would
likely have inherently higher risk characteristics that made
a CMR the test choice compared with echocardiography or
MPI. However, the diagnostic yield, as reﬂected by the
proportion of patients with a positive stress CMR, was 32%,
suggesting that the study population was of intermedi-
ate pretest risk for CAD. The meta-analysis was also
overwhelmingly based on 1.5-T imaging. Emerging data
suggest that 3-T stress CMR has superior diagnostic
performance (13).
CMR has the unique capability to provide a comprehen-
sive cardiovascular evaluation in 1 session previously avail-
able only by combining multiple modalities. It offers
superior spatial resolution in the assessment of ischemia and
the function and structure of both ventricles and valves. It
can also directly characterize whether ischemic tissue is
viable or nonviable, thereby providing information as to
whether a patient is likely to beneﬁt from invasive cathe-
terization and/or revascularization. Experimental CMR
sequences that directly identify vulnerable plaques are also
under active investigation (14). However, it remains to be
proven whether the additional information gained from this
comprehensive examination is of clinical utility. Indeed,
studies have demonstrated that each component of
a comprehensive CMR examination (i.e., stress perfusion,
LGE, ﬂow, left ventricular structure and function) add
incremental prognostic information over each other (15),
suggesting each component to be additive rather than
redundant in predicting risk. Future studies are needed to
clarify the role of the comprehensive cardiac examination.
What is the role of stress CMR, therefore, in the context
of an era of overtesting? The next logical step would be the
direct comparison of prognosis in similar populations using
these 3 modalities, as well as comparing the cost-effectiveness
of each test strategy (16,17). In a recent model-based anal-
ysis, Boldt et al. (17) demonstrated the superior cost-
effectiveness of stress CMR compared with single-photon
emission computed tomography in Germany for diagnosing
suspected CAD in patients with low to intermediate pretest
probability of CAD. Whether this analysis can be general-
izable in other settings will require further validation. Using
this information, appropriate-use criteria need to be carefully
drafted to ensure the optimal use of these imaging technol-
ogies for the right clinical scenario in the right patient
population, taking into account factors such as local expertise,
current infrastructure, and support personnel. The ultimate
goal is to avoid unnecessary testing.
In summary, we congratulate Lipinski et al. (9) for
providing validation of the high negative predictive value of
stress CMR in risk stratiﬁcation of patients with established
or suspected CAD. Those without ischemia on stress CMR
have a very favorable intermediate-term prognosis, whereas
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841a positive test identiﬁes high-risk patients. One cannot
deny the attractiveness of a test that is free of ionizing
radiation, accurate, and potentially cost-effective. There is
now ample evidence to support the use of stress CMR as
a prognostic tool, accurately differentiating between low-
risk and high-risk patients. Although important questions
remain unanswered with regard to the clinical utility of
a comprehensive CMR examination, it is due time for the
cardiology community to trust the magnetic crystal ball!Reprint requests and correspondence: Dr. Warren J. Manning,
Department of Medicine, Cardiovascular Division, Beth Israel
Deaconess Medical Center, 330 Brookline Avenue, Boston,
Massachusetts 02215. E-mail: wmanning@bidmc.harvard.edu.
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